坎格瑞洛在合并心源性休克及心肺复苏后患者中的应用:全球多中心配对分析与IABP-SHOCK II试验口服P2Y12抑制剂的比较
该研究为全球多中心回顾性配对分析,纳入136例接受坎格瑞洛治疗的心源性休克PCI患者,按年龄、性别、心脏骤停、心梗类型、罪犯病变、糖蛋白IIb/IIIa抑制剂及口服P2Y12抑制剂使用与IABP-SHOCK II试验中未用坎格瑞洛的休克患者1:1匹配,最终形成88对。结果显示坎格瑞洛组30天和12个月死亡率分别为29.5%和34.1%,对照组为36.4%和47.1%(P=0.34和P=0.08),两组明确急性支架血栓率均为2.3%,中重度出血分别为21.6%和19.3%(P=0.71)。坎格瑞洛组PCI术中TIMI血流分级改善≥1级的比例更高(92.9% vs 81.2%,P=0.02)。作者认为坎格瑞洛在心源性休克中可能是安全有效的抗血小板选择,需随机试验进一步评估。
要点
- 在心源性休克接受PCI的患者中,坎格瑞洛组30天死亡率29.5%、12个月死亡率34.1%,对照组分别为36.4%和47.1%,差异未达统计学显著(P=0.34和P=0.08)。
- 坎格瑞洛组与口服P2Y12抑制剂组中重度出血发生率分别为21.6%和19.3%,差异无统计学意义(P=0.71)。
- 两组明确急性支架血栓发生率均为2.3%。
- 坎格瑞洛组PCI术中TIMI血流分级改善≥1级的比例显著高于对照组(92.9% vs 81.2%,P=0.02)。
- 作者认为坎格瑞洛在心源性休克中可能是安全有效的抗血小板选择,需随机试验进一步评估。
适用人群与场景
- 回顾性纳入136例接受坎格瑞洛治疗的心源性休克并接受经皮冠状动脉介入治疗的患者,与IABP-SHOCK II试验中未接受坎格瑞洛的心源性休克患者按年龄、性别、心脏骤停、心肌梗死类型、罪犯病变、糖蛋白IIb/IIIa抑制剂及口服P2Y12受体抑制剂使用进行1:1匹配,最终分析88对匹配患者,随访12个月。
研究设计与关键结果
- 研究类型为全球多中心回顾性配对分析,最终纳入88对匹配的心源性休克PCI患者,比较坎格瑞洛与口服P2Y12抑制剂的临床结局。
- 主要终点方面,坎格瑞洛组30天死亡率为29.5%,对照组为36.4%(P=0.34);12个月死亡率坎格瑞洛组为34.1%,对照组为47.1%(P=0.08),均未达统计学显著。
- 两组明确急性支架血栓发生率均为2.3%。
- 中度和重度出血事件在坎格瑞洛组发生率为21.6%,对照组为19.3%(P=0.71),差异无统计学意义。
- 坎格瑞洛组PCI术中TIMI血流分级改善≥1级的患者比例显著高于对照组(92.9% vs 81.2%,P=0.02)。
证据类型、等级与局限
- 证据类型为全球多中心回顾性配对分析。
- 作者在结论中指出坎格瑞洛在心源性休克中可能是安全有效的抗血小板选择,并明确提出需在随机试验中进一步评估。
对床旁实践的改变
- 对于心源性休克接受PCI的患者,该回顾性配对分析提示使用坎格瑞洛与口服P2Y12抑制剂相比出血风险相似,且与更高的TIMI血流改善率相关(92.9% vs 81.2%,P=0.02),但死亡率和支架血栓率无显著差异;作者认为坎格瑞洛可能是安全有效的抗血小板选择,需随机试验进一步评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIMS: Cangrelor has a potentially favorable pharmacodynamic profile in cardiogenic shock (CS). We aimed to evaluate the clinical course of CS patients undergoing percutaneous coronary intervention (PCI) treated with cangrelor.
METHODS AND RESULTS: We retrospectively identified 136 CS patients treated with cangrelor. Patients were 1:1 matched to CS patients from the IABP-SHOCK II trial not receiving cangrelor by age, sex, cardiac arrest, type of myocardial infarction, culprit lesion, glycoprotein IIb/IIIa inhibitor, and oral P2Y12-receptor inhibitor and followed-up for 12 months. The study cohort consisted of 88 matched pairs. Thirty-day and 12-month mortality was 29.5% and 34.1% in cangrelor-treated patients and 36.4% and 47.1% in control group (P = 0.34 and P = 0.08, respectively). The rate of definite acute stent thrombosis was 2.3% in both groups. Moderate and severe bleeding events occurred in 21.6% in the cangrelor and 19.3% in the control group (P = 0.71). Patients treated with cangrelor more frequently experienced ≥1 TIMI flow grade improvement during PCI (92.9% vs. 81.2%, P = 0.02).
CONCLUSION: Cangrelor treatment was associated with similar bleeding risk and significantly better TIMI flow improvement compared with oral P2Y12 inhibitors in CS patients undergoing PCI. The use of cangrelor in CS offers a potentially safe and effective antiplatelet option and should be evaluated in randomized trials.
参考来源
- Droppa M, Vaduganathan M, Venkateswaran RV, et al. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation. 2019. PMID: 30790690. doi:10.1016/j.resuscitation.2019.02.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。